Zora Biosciences Oy, Biologinkuja 1, 02150, Espoo, Finland.
Department of Internal Medicine, Oulu University Hospital, Oulu, Finland.
Diabetologia. 2018 Jun;61(6):1424-1434. doi: 10.1007/s00125-018-4590-6. Epub 2018 Mar 15.
AIMS/HYPOTHESIS: Ceramide lipids have a role in the development of insulin resistance, diabetes and risk of cardiovascular disease. Here we investigated four ceramides and their ratios to find the best predictors of incident diabetes.
A validated mass-spectrometric method was applied to measure Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:0) and Cer(d18:1/24:1) from serum or plasma samples. These ceramides were analysed in a population-based risk factor study (FINRISK 2002, n = 8045), in a cohort of participants undergoing elective coronary angiography for suspected stable angina pectoris (Western Norway Coronary Angiography Cohort [WECAC], n = 3344) and in an intervention trial investigating improved methods of lifestyle modification for individuals at high risk of the metabolic syndrome (Prevent Metabolic Syndrome [PrevMetSyn], n = 371). Diabetes risk score models were developed to estimate the 10 year risk of incident diabetes.
Analysis in FINRISK 2002 showed that the Cer(d18:1/18:0)/Cer(d18:1/16:0) ceramide ratio was predictive of incident diabetes (HR per SD 2.23, 95% CI 2.05, 2.42), and remained significant after adjustment for several risk factors, including BMI, fasting glucose and HbA (HR 1.34, 95% CI 1.14, 1.57). The finding was validated in the WECAC study (unadjusted HR 1.81, 95% CI 1.53, 2.14; adjusted HR 1.39, 95% CI 1.16, 1.66). In the intervention trial, the ceramide ratio and diabetes risk scores significantly decreased in individuals who had 5% or more weight loss.
CONCLUSIONS/INTERPRETATION: The Cer(d18:1/18:0)/Cer(d18:1/16:0) ratio is an independent predictive biomarker for incident diabetes, and may be modulated by lifestyle intervention.
目的/假设:神经酰胺脂质在胰岛素抵抗、糖尿病和心血管疾病风险的发展中起作用。在这里,我们研究了四种神经酰胺及其比值,以寻找预测糖尿病发病的最佳指标。
应用经过验证的质谱法测量血清或血浆样本中的 Cer(d18:1/16:0)、Cer(d18:1/18:0)、Cer(d18:1/24:0)和 Cer(d18:1/24:1)。这些神经酰胺在一项基于人群的危险因素研究(FINRISK 2002,n=8045)、一项因疑似稳定型心绞痛行选择性冠状动脉造影的参与者队列研究(Western Norway Coronary Angiography Cohort [WECAC],n=3344)和一项针对代谢综合征高危个体的生活方式改善方法的干预试验中进行了分析(Prevent Metabolic Syndrome [PrevMetSyn],n=371)。建立了糖尿病风险评分模型来估计 10 年内发生糖尿病的风险。
在 FINRISK 2002 中的分析表明,Cer(d18:1/18:0)/Cer(d18:1/16:0)神经酰胺比值可预测糖尿病发病(每标准差 HR 2.23,95%CI 2.05,2.42),并且在调整包括 BMI、空腹血糖和 HbA 在内的多个危险因素后仍然具有显著性(HR 1.34,95%CI 1.14,1.57)。这一发现在 WECAC 研究中得到了验证(未经调整的 HR 1.81,95%CI 1.53,2.14;调整后的 HR 1.39,95%CI 1.16,1.66)。在干预试验中,Cer(d18:1/18:0)/Cer(d18:1/16:0)比值和糖尿病风险评分在体重减轻 5%或更多的个体中显著降低。
结论/解释:Cer(d18:1/18:0)/Cer(d18:1/16:0)比值是糖尿病发病的独立预测生物标志物,并且可能受到生活方式干预的调节。